Matt Hewitt
Stock Analyst at Craig-Hallum
(2.75)
# 2,010
Out of 4,964 analysts
40
Total ratings
54.05%
Success rate
4.61%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $14.36 | +150.70% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.60 | +81.82% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.69 | +123.05% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $25.43 | +25.84% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $33.27 | +92.39% | 6 | Oct 31, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $1.76 | +468.18% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $19.79 | +51.59% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $1.40 | +400.00% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $118.88 | +68.24% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $1.61 | +521.12% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $7.74 | +287.60% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.74 | +53,939.45% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $14.36
Upside: +150.70%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.60
Upside: +81.82%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.69
Upside: +123.05%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $25.43
Upside: +25.84%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $33.27
Upside: +92.39%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $1.76
Upside: +468.18%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $19.79
Upside: +51.59%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $1.40
Upside: +400.00%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $118.88
Upside: +68.24%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.61
Upside: +521.12%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $7.74
Upside: +287.60%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.74
Upside: +53,939.45%